Drug discovery is undergoing a profound shift. After decades of incremental change, the rapid maturation of AI-powered modelling and simulation tools is beginning to rewrite the scientific method itself.
The industry now stands at an inflexion point where computational prediction and experimental validation are no longer sequential activities but part of a tightly unified cycle — accelerating timelines, sharpening decision making and redrawing competitive lines across the sector.
A central driver of this transformation is the direct integration of advanced structure prediction and binding-simulation capabilities into laboratory informatics platforms.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.